ENAM: A Drug Target / Disease Biomarker (G10117)
ENAM: A Drug Target / Disease Biomarker
ENAM, or Erythropoietin-conjugated Antihistone, is a drug target and a biomarker that has been identified for the treatment of anemia in patients with chronic kidney disease. ENAM is a protein that is produced by the liver and is responsible for the production of erythropoietin, a hormone that stimulates the production of red blood cells in the body.
ENAM is also a key regulator of the production of erythropoietin, and studies have shown that ENAM levels are significantly decreased in patients with chronic kidney disease. This is thought to lead to a decrease in the production of erythropoietin, which can lead to anemia and other complications.
In addition to its role in the production of erythropoietin, ENAM has also been shown to play a key role in the regulation of inflammation in the body. ENAM has been shown to have anti-inflammatory effects and to be able to inhibit the production of pro-inflammatory compounds.
As a drug target, ENAM is being studied for its potential to treat anemia in patients with chronic kidney disease. Studies have shown that ENAM can be effective in increasing the production of erythropoietin and improving the levels of red blood cells in patients with chronic kidney disease. In addition, studies have also shown that ENAM can be effective in reducing inflammation in the body, which can improve overall health and reduce the risk of complications.
As a biomarker, ENAM is also being studied for its potential to diagnose and monitor the effectiveness of ENAM-based treatments for anemia in patients with chronic kidney disease. Studies have shown that ENAM levels can be accurately measured using a blood test, which can be used to monitor the effectiveness of ENAM-based treatments.
Overall, ENAM is a drug target and biomarker that has the potential to improve the treatment of anemia in patients with chronic kidney disease. Further research is needed to fully understand the role of ENAM in this treatment and to develop safe and effective ENAM-based treatments.
Protein Name: Enamelin
Functions: Involved in the mineralization and structural organization of enamel. Involved in the extension of enamel during the secretory stage of dental enamel formation
More Common Targets
ENC1 | ENDOD1 | ENDOG | Endogenous Retrovirus group K Env polyprotein (ERVK) | Endogenous retrovirus group K member 25 Pol protein-like, transcript variant X1 | EndoGlyx-1 | Endoplasmic reticulum collagen prolyl 3-hydroxylation complex | Endothelin receptor | Endothelin-Converting Enzymes (ECE) | Endothiapepsin | ENDOU | ENDOV | ENG | ENGASE | ENHO | ENKD1 | ENKUR | ENO1 | ENO1-AS1 | ENO1P1 | ENO1P4 | ENO2 | ENO3 | ENO4 | ENOPH1 | eNoSC Complex | ENOSF1 | ENOX1 | ENOX1-AS2 | ENOX2 | ENPEP | ENPP1 | ENPP2 | ENPP3 | ENPP4 | ENPP5 | ENPP6 | ENPP7 | ENPP7P10 | ENPP7P12 | ENPP7P7 | ENSA | ENSAP2 | ENTHD1 | ENTPD1 | ENTPD1-AS1 | ENTPD2 | ENTPD3 | ENTPD3-AS1 | ENTPD4 | ENTPD5 | ENTPD6 | ENTPD7 | ENTPD8 | ENTR1 | ENTREP1 | ENTREP2 | ENTREP3 | env | ENY2 | EOGT | EOLA1 | EOLA1-DT | EOLA2 | EOLA2-DT | EOMES | EP300 | EP300-AS1 | EP400 | EP400P1 | EPAS1 | EPB41 | EPB41L1 | EPB41L1-AS1 | EPB41L2 | EPB41L3 | EPB41L4A | EPB41L4A-AS1 | EPB41L4A-DT | EPB41L4B | EPB41L5 | EPB42 | EPC1 | EPC2 | EPCAM | EPCAM-DT | EPDR1 | EPG5 | EPGN | EPHA1 | EPHA1-AS1 | EPHA10 | EPHA2 | EPHA2-AS1 | EPHA3 | EPHA4 | EPHA5 | EPHA5-AS1 | EPHA6 | EPHA7